InterveXion has been granted a meeting with FDA in January 2014 to discuss the development program for ch-mAb7F9. The purpose of the meeting is three-fold: 1) to discuss the results of the Phase 1a study, 2) to confirm that the proposed nonclinical studies will support a Phase 1b trial in METH-using subjects, and 3) to review the Phase 1b study protocol.